THE $65 BILLION OPPORTUNITY
Every day a clinical trial misses its enrollment deadline, sponsors lose $600,000 to $8 million. This happens to 80% of trials. Over the life of a trial, enrollment delays can add $50 million or more in unexpected costs.
Patient recruitment is the #1 bottleneck in drug development—and the biggest opportunity.
The clinical trial services market is $65 billion and growing 12% annually. Patient recruitment platforms have achieved multiple nine-figure exits. New FDA diversity mandates create additional tailwinds for companies with the right capabilities.
We're building the next platform to capture this opportunity.
5 REASONS INVESTING IS A NO-BRAINER
FOUNDER BUILT THIS BEFORE
You're not funding someone learning on your dime.
Our founder was Senior Marketing Manager at a leading patient recruitment platform before its nine-figure acquisition. He knows the playbook, the pitfalls, and the path to exit—because he's traveled it before.
RARE EXPERTISE CONVERGENCE
This trifecta doesn't exist anywhere else.
Most patient recruitment founders have ONE of these. We have all three.
PROVEN MODEL—NOT AN EXPERIMENT
We're replicating a model that has driven multiple nine-figure exits.
The patient recruitment business model is proven: digital patient acquisition, rigorous pre-screening, technology platform for sites and sponsors, performance-based pricing. Multiple companies have scaled this model to nine-figure valuations.
MULTIPLE EXIT PATHS PROVEN
Strategic acquirers are actively buying patient recruitment capabilities.
THE MATH WORKS
Clear returns at realistic exit valuations.
These aren't fantasy numbers—they're based on comparable exits in this space.
5 STRATEGIES THAT SCALE TO NINE FIGURES
These are the strategies that powered nine-figure exits—and we're implementing all of them:
PERFORMANCE-BASED PRICING
Clients pay for enrolled patients, not leads or activity. This eliminates client risk and creates perfect alignment.
DIGITAL PATIENT ACQUISITION AT SCALE
Patients are online, searching for treatment options. We reach them through Facebook, Google, and programmatic networks. This scales infinitely.
RIGOROUS PRE-SCREENING
Contacting patients within minutes and verifying eligibility before site referral. This reduces screen failures from 50%+ to 10-15%—sites love us.
ENTERPRISE CRO PARTNERSHIPS
Portfolio-level deals with major CROs create recurring revenue. One Tier 1 CRO partnership can represent $5M+ annually.
REGULATORY TAILWIND (FDA DIVERSITY)
FDA's 2025 Diversity Action Plan requirements create mandatory demand. Our bilingual capabilities give us an unfair advantage.
5-7 YEAR EXIT PLAN
We are building to exit within 5-7 years maximum. Here's the specific roadmap:
FOUNDATION & TRACTION
SCALE & MARKET POSITION
EXIT EXECUTION
FINANCIAL PROJECTIONS
UNIT ECONOMICS
REVENUE PROJECTIONS
INVESTMENT OPPORTUNITIES
All investments include preferred equity, 2x liquidation preference, anti-dilution protection, monthly reporting, and pro-rata rights.
USE OF FUNDS
IDEAL INVESTOR PROFILES
Healthcare/Biotech Angels
Former pharma executives, healthcare entrepreneurs who understand the market
Former Pharma/CRO Executives
Leaders who spent careers frustrated by enrollment delays
Impact Investors
Seeking healthcare impact—faster drug development means patients get treatments sooner
Strategic Partners
CROs or pharmaceutical companies seeking recruitment capabilities
LEADERSHIP
NEXT STEPS
15 minutes. We'll show you exactly how the model works and when you'll see returns.